Drug Database
PA

pantoprazole

✓ Approved

Nanodaru · ATP4A · Small Molecule

What is pantoprazole?

pantoprazole is a small molecule developed by Nanodaru. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyNanodaru
Drug ClassSmall Molecule
Molecular TargetATP4A
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Mechanism of Action

Molecular Targets

pantoprazole acts on 1 molecular target:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pantoprazole is developed for 4 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Gastrointestinal disordersDuodenal ulcer✓ Approved
Gastrointestinal disordersGastric ulcer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Gastrinoma✓ Approved
Gastrointestinal disordersGastrooesophageal reflux disease✓ Approved

Related Research Articles

PubMedThe American journal of tropical medicine and hygiene2026-07-17

Eyelid Verrucous Sporotrichosis Caused by Sporothrix Brasiliensis Mimicking Cutaneous Leishmaniasis and Complicated by Drug-Drug Interaction.

Rodrigues Felipe Tavares FT, Dos Santos Amanda Ribeiro AR, de Almeida Sandro Rogério SR, Albuquerque Renata Chaves RC et al.

Sporotrichosis caused by Sporothrix brasiliensis is endemic in Brazil and may present with atypical clinical features. We report a case of verrucous sporotrichosis of the eyelid mimicking cutaneous leishmaniasis in a 28-year-old woman without cat exposure or trauma. Initial diagnostic studies were inconclusive, and prolonged treatment with oral itraconazole failed. Subsequent fungal culture and polymerase chain reaction established the diagnosis. Medication review revealed concomitant pantoprazole use, likely impairing itraconazole absorption through pH-dependent bioavailability. Lesion resolution occurred after a 3-month course of oral terbinafine. This case highlights two critical considerations: sporotrichosis should remain in the differential diagnosis of chronic verrucous lesions in endemic regions, and careful evaluation of drug-drug interactions is essential to prevent antifungal treatment failure.

PubMedJournal of gastroenterology and hepatology2026-07-13

High-Dose Oral Omeprazole Versus Continuous Intravenous Pantoprazole in Patients With High-Risk Peptic Ulcer Bleeding: A Single-Blinded Multicenter RCT.

Sriyudthsak Kanteera K, Nalinthassanai Nutbordee N, Sriapiraksa Bunyos B, Rattanachaisit Pakkapon P et al.

The efficacy of high-dose oral omeprazole in peptic ulcer bleeding after successful therapeutic hemostatic endoscopy has not been well established. This study aimed to compare the efficacy of high-dose oral omeprazole versus continuous intravenous (IV) pantoprazole in rebleeding and percent time of gastric pH above 6. Eligible patients were randomized with 1:1 concealed allocation to 40-mg oral omeprazole twice daily or IV pantoprazole 8 mg/h for 72 h after index gastroscopy. Gastric pH was measured for 24 h during 48-72 h after starting the assigned medication. Rebleeding at 72 h and 30 days, as well as 24-h gastric pH, were assessed. A total of 124 patients were analyzed. Seventy-two-hour rebleeding occurred in 1.6% (1/61) of the oral omeprazole group and 4.8% (3/63) of the IV pantoprazole group requiring endoscopic hemostasis (risk difference [RD] -3.1%, 95% CI -11.6% to 4.6%). Rebleeding within 30 days also showed no difference between groups (3.3% vs. 4.8%, RD -1.5%, 95% CI -10.1% to 7.0%). Gastric pH monitoring was completed in 48% (29/61) of the oral group and 41% (26/63) of the IV group. The median percentage of gastric pH > 6 was 56.3% (IQR 28.0%-92.0%) in the oral group and 27.3% (IQR 4.4%-77.7%) in the IV group (p = 0.064). High-dose oral omeprazole may represent a feasible alternative to continuous IV pantoprazole in terms of preventing rebleeding at 72 h and 30 days and maintaining gastric pH > 6 among patients with peptic ulcer bleeding who underwent successful therapeutic hemostatic endoscopy. Registration number: NCT04394663.

PubMedArchiv der Pharmazie2026-07-13

Gastroprotective Activity of Myrtenol Derivatives Obtained by Biocatalytic Esterification and Photooxidation.

Viana Ana Flávia Seraine Custódio AFSC, Kutyła Mateusz M, de Barros Fernandes Hélio H, Acha Boris Timah BT et al.

Many naturally occurring substances exhibit anti-ulcer properties. One promising area of research is the identification of terpenoid compounds with enhanced therapeutic and gastroprotective properties. The present study aimed to synthesize new terpenoid derivatives of myrtenol via biotransformation using freeze-dried Cladosporium cladosporioides mycelium or via porphyrin-based biomimetic transformation, and to evaluate their gastroprotective activity in an ethanol-induced gastric lesion model. Five myrtenyl esters (acetate, butyrate, caprylate, pelargonate, and laurate) and two oxidative derivatives (myrtenal and myrtenal oxide) were obtained with a high degree of purity (> 94%, GC). The anti-ulcer preventive effects of the compounds were evaluated in mice at doses ranging from 6.25 to 25 mg per kg of body weight. The mice were treated orally prior to the induction of ethanol-induced gastric lesions. All compounds exerted a gastroprotective effect, reducing the lesion area (mm2) compared to the negative control group. Notably, the gastroprotective effects of myrtenyl caprylate, myrtenyl pelargonate, and myrtenyl laurate were equivalent to those promoted by the clinical medicine pantoprazole.

PubMedCureus2026-07-11

Gastric Antral Vascular Ectasia as an Uncommon Cause of Upper Gastrointestinal Bleeding: A Case Report.

Muhtadi Rakin R, Katz Kenneth D KD

Gastric antral vascular ectasia (GAVE) can result in upper gastrointestinal bleeding (UGIB) and is an important diagnostic consideration, especially in the elderly. It is often mistaken for portal hypertensive gastropathy given its similar endoscopic appearances and occurrence in comparable patient populations. We present the case of an elderly patient who presented to the emergency department (ED) with UGIB due to GAVE. A 75-year-old female patient with a past medical history of peptic ulcer disease, hypertension, rheumatoid arthritis, and type II diabetes mellitus presented to the ED for repeat syncopal episodes, nausea, diarrhea, and fatigue. The patient had melanotic stool, significant blood-loss anemia, and an abdominal computed tomography (CT) scan showing hepatic cirrhosis. The patient was administered intravenous packed red blood cells, ceftriaxone, octreotide, and pantoprazole, and was admitted to the hospital. Esophagogastroduodenoscopy (EGD) showed no varices but GAVE, which was then treated with argon plasma coagulation. The patient experienced no further bleeding and was discharged on hospital day 3. GAVE is a rare cause of UGIB with which emergency physicians should be familiar. Immediate stabilization in the ED, followed by prompt and direct endoscopic therapy, is critical for its treatment.

PubMedActa neurobiologiae experimentalis2026-06-29

Chronic pantoprazole exposure induces behavioral deficits and region‑specific molecular changes in the rat motor cortex and cerebellum.

Caglar Emine E, Elibol Birsen B, Polat Nurhayat N, Dursun Ilknur I

Proton pump inhibitors are widely used, but their long‑term effects on the central nervous system are not well understood. In this study, we investigated whether chronic pantoprazole use alters sensorimotor function, oxidative stress, inflammatory response, and apoptosis in the motor cortex and cerebellum. Twenty‑one female Wistar rats were randomized to control (C), gavage control (GC), or pantoprazole (P; 20 mg/kg/day for 12 weeks) groups. Sensorimotor coordination (rotarod), water‑maze swim velocity, and open‑field locomotion were assessed as behavioral parameters. The cortical and cerebellar tissues were analyzed by Enzyme‑Linked Immunosorbent Assay (ELISA) for apoptosis, inflammation, and oxidative stress. Pantoprazole impaired sensorimotor coordination compared to both control groups. However, its effects on swim velocity and locomotor activity were primarily significant when compared to the naive control group, suggesting that gavage‑related stress may have contributed to these behavioral outcomes. Bcl‑2‑associated X protein (BAX) and Bcl‑2 associated agonist of cell death (BAD) protein levels and the BAX/Bcl‑2 ratio increased with pantoprazole, particularly in the motor cortex, indicating enhanced pro‑apoptotic activity. While tumor necrosis factor levels did not change, interleukin (IL)‑6 and IL‑1β levels were significantly higher in the cerebellum, suggesting neuroinflammatory activation associated with both pantoprazole and gavage‑induced stress. Furthermore, oxidative stress analyses revealed elevated malondialdehyde and oxidative stress index levels, as well as increased total antioxidant status, in specific regions, suggesting an imbalance between oxidative and antioxidant responses. Chronic pantoprazole administration resulted in modest motor deficits and region‑specific molecular alterations, including a pro‑apoptotic shift in the motor cortex. In addition, an inflammatory/compensatory antioxidant response in the cerebellum was observed due to both gavage‑induced stress and pantoprazole administration. These findings highlight the need for further studies on dose‑response, reversibility, and synaptic consequences, and suggest the importance of considering the risks of prolonged proton pump inhibitors exposure.

PubMedThe Journal of international medical research2026-06-27

Monitoring and analysis of drug therapy in a patient with drug reaction with eosinophilia and systemic symptoms syndrome caused by pantoprazole: A case report.

Chen Guang-Hui GH, Lei Hai-Bo HB, Liu Xiang X, Zheng Yun-Hua YH

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe T-cell-mediated adverse cutaneous reaction characterized by rash, fever, and visceral involvement following prolonged drug use. It is rarely induced by proton pump inhibitors, with no prior reports documenting pharmacist-identified pantoprazole-related DRESS syndrome and subsequent intervention. A female in her early 60s (Han Chinese ethnicity) was admitted to the intensive care unit of Xiangtan Central Hospital (Xiangtan, China) in mid-2024 for thoracoabdominal pain caused by a fall, and pantoprazole was initiated for stress ulcer prophylaxis on the hospital day 2. Twenty-six days after pantoprazole initiation, the patient developed diffuse macular erythema with desquamation, and her eosinophil percentage increased from 0.5% to 7.8% after 2 days of rash onset. The clinical pharmacist initially suspected meropenem hypersensitivity and recommended discontinuation of this agent; however, 5 days after the onset of rash, leucopenia was observed with the eosinophil percentage peaking at 18.4%, and subsequent discontinuation of pantoprazole resulted in defervescence within 48 h, gradual resolution of the rash, and normalization of blood counts within approximately 10 days of drug cessation. Despite the complex pathophysiology and diagnostic challenges associated with DRESS syndrome, the pharmacist's identification of the suspected drug and targeted intervention achieved favorable outcomes, providing clinical reference for further research on DRESS syndrome.

+2386 more articles available with a free account

Sign up free to view all articles →

Ask about pantoprazole